Deferasirox granule formulation + Deferasirox DT formulation
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusion-dependent Anemia
Conditions
Transfusion-dependent Anemia
Trial Timeline
Oct 21, 2015 → Jan 15, 2024
NCT ID
NCT02435212About Deferasirox granule formulation + Deferasirox DT formulation
Deferasirox granule formulation + Deferasirox DT formulation is a phase 2 stage product being developed by Novartis for Transfusion-dependent Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02435212. Target conditions include Transfusion-dependent Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02435212 | Phase 2 | Completed |
Competing Products
8 competing products in Transfusion-dependent Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 52 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferoxamine + Deferasirox | Novartis | Approved | 85 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 25 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 25 |